News

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic…
Read More...

Repare Therapeutics Inc. announced that, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40…
Read More...

Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces an expanded commitment to developing tailored cancer vaccines…
Read More...

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being…
Read More...

Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc.…
Read More...

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA (erdafitinib) for the treatment…
Read More...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases,…
Read More...

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the U.S. Food and Drug Administration (FDA) has granted Fast…
Read More...

BridgeBio Pharma, Inc. (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced strategic financing from Blue Owl…
Read More...

Halozyme Therapeutics, Inc. announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc)…
Read More...

Roche announced that the European Commission has granted marketing authorisation for Tecentriq SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved HYQVIA  for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance…
Read More...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY (exagamglogene autotemcel ), a CRISPR/Cas9 gene-edited cell therapy,…
Read More...

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced…
Read More...

Myrobalan Therapeutics, a biotechnology company developing novel oral neurorestorative therapies to repair damage and restore neural function in high-unmet need degenerative CNS…
Read More...

GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on maintenance treatment for severe eosinophilic asthma in adults…
Read More...

GSK plc and Aiolos Bio, Inc. (Aiolos) announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on…
Read More...

Vertex Pharmaceuticals Incorporated announced that the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGEVY (exagamglogene autotemcel ), a CRISPR/Cas9…
Read More...

Alcon announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the…
Read More...